Licensee Estoppel

Licensee estoppel was a common law doctrine preventing a patent licensee from challenging the validity of the licensed patent while the license remained in force: ORIGINAL DOCTRINE: under the old rule, a licensee who had accepted a patent license was estopped — barred — from later claiming the patent was invalid; the theory was that having accepted the license benefits, the licensee should not be allowed to 'bite the hand that fed it' by challenging the validity of the underlying right; LEAR, INC. v. ADKINS (S.Ct. 1969): the Supreme Court abolished licensee estoppel by a 5-4 vote; facts: Adkins developed a gyroscope and licensed his invention to Lear before a patent was issued; after patent issuance, Lear stopped paying royalties and challenged the patent as invalid; the California Supreme Court upheld estoppel; the Supreme Court reversed; REASONING: the Court prioritized the PUBLIC INTEREST IN EXPOSING INVALID PATENTS over the private interest in contract stability; federal patent policy disfavors enforcement of invalid patents; a licensee who knows a patent is invalid is uniquely positioned to challenge it; the royalty burden itself creates an incentive to challenge invalid patents; allowing estoppel would permit patentees to silence the party most likely to mount a successful challenge; RESULT OF LEAR: a patent licensee may challenge the validity of the licensed patent at any time — including while continuing to practice the license and pay royalties; a successful invalidity challenge voids the patent and terminates the royalty obligation; the licensee may also seek to recover past royalties paid on an invalid patent (in some jurisdictions).

Since Lear, courts have defined the scope of the challenge right and identified its limits: WHAT LEAR PERMITS: a patent licensee may challenge patent validity in federal court even while the license remains in force; the licensee may withhold royalties while the validity challenge is pending (accepting the risk of damages if the patent is upheld); the licensee may assert invalidity as a defense in a patent infringement suit; LIMITS OF LEAR — TIMING OF CHALLENGE: Lear does not prevent enforcement of contractual provisions that require the licensee to pay royalties before challenging validity; some license agreements require continued payment during any validity challenge — courts generally enforce these provisions because the licensee retains the right to challenge, just with continued payment as a condition; LIMITS — ANTITRUST/FRAUD CLAIMS: the Lear doctrine relates to contract estoppel; it does not create a cause of action for invalidity outside the context of an existing dispute; BUT it does enable invalidity challenges as defenses in infringement suits and as bases for declaratory judgment actions; LIMITS — ASSIGNOR ESTOPPEL: Lear did NOT abolish assignor estoppel; an inventor who assigns a patent (and receives consideration for it) cannot later challenge the patent's validity; Minerva Surgical v. Hologic (S.Ct. 2021): reaffirmed assignor estoppel with some limits; the logic is different: the inventor warranted patentability upon assignment, creating equitable estoppel; SUBLICENSEES: licensees' sublicensees are also not estopped under Lear; DECLARATORY JUDGMENT: after Lear, licensees could use declaratory judgment actions to challenge patent validity pre-suit, though later cases (MedImmune v. Genentech, S.Ct. 2007) resolved that even licensees who are paying royalties can maintain DJ actions challenging patent validity.

Lear abolished licensee estoppel but left assignor estoppel intact — based on a different equitable foundation: LICENSEE ESTOPPEL (ABOLISHED BY LEAR): arose from a contractual relationship; licensee received a patent license; licensee's promise not to challenge was implied from the license contract; abolished because public interest in exposing invalid patents outweighs contract stability; ASSIGNOR ESTOPPEL: arises from an assignment — the inventor (or employer) transfers the patent to another party and receives consideration; the inventor implicitly or expressly warranted patentability; EQUITY: it would be 'unfair' to allow the inventor to take money for the patent and then argue the patent is worthless; this is the basis for Westinghouse Electric v. Formica Insulation Co. (S.Ct. 1924) and Minerva Surgical v. Hologic (S.Ct. 2021); MINERVA SURGICAL (S.Ct. 2021): the Supreme Court reaffirmed assignor estoppel but limited its scope; a party is estopped only from making arguments that contradict specific REPRESENTATIONS made in the original assignment; if the assigned patent issues with BROADER CLAIMS than the original application's claims, the assignor is NOT estopped from challenging the broader claims (because the representation went to the original, narrower claims); KEY DIFFERENCE: assignor estoppel = equitable warranty by transferor (who made money on transfer); licensee estoppel = contractual estoppel by transferee (who receives benefits under the patent); Lear removed contractual estoppel to promote patent validity challenges; Minerva limited (but preserved) equitable estoppel based on inconsistent positions.

MedImmune, Inc. v. Genentech, Inc. (S.Ct. 2007) extended the right of licensees to challenge patent validity without breaching the license: BACKGROUND: MedImmune was a licensee under a Genentech patent; MedImmune believed the patent was invalid but feared that terminating the license and challenging the patent would expose it to infringement damages; instead, MedImmune continued paying royalties under protest and sought a declaratory judgment that the patent was invalid; QUESTION: did MedImmune have standing to file a DJ action while still paying royalties (and thus arguably not under an 'actual or immediate threat' of infringement suit)? HOLDING: yes — the Supreme Court held that MedImmune had standing to challenge patent validity via a declaratory judgment action even while continuing to pay royalties; the licensee is not required to risk infringement liability and stop paying royalties in order to create a justiciable controversy for DJ purposes; PRE-MEDIMMUNE RULE: before MedImmune, some courts required a licensee to breach the license (stop paying royalties) before a DJ challenge was ripe; this created the Hobson's choice: either pay invalid royalties forever or breach and face infringement damages; MEDIMMUNE'S IMPACT: removed the 'shoot first then ask forgiveness' requirement; licensees can challenge validity from the safety of a continuing license; licensors lose the ability to silence challenges by pointing to the non-breaching licensee's lack of controversy; INTERACTION WITH LEAR: Lear established the right to challenge; MedImmune cleared the procedural path to challenge without risking license breach.

Licensors have developed various contractual strategies to manage the risk of licensee validity challenges after Lear: CONTINUED PAYMENT CLAUSES: require the licensee to continue paying royalties during any validity challenge (Lear does not prohibit payment conditions — only estoppel from challenging); some courts enforce these provisions because the licensee still retains the right to challenge; NOTICE REQUIREMENTS: require the licensee to provide advance notice of any validity challenge; allows the licensor time to prepare and potentially cure deficiencies; CHALLENGE FEE PROVISIONS: some licenses require the licensee to pay a fee (or increased royalty rate) if it initiates a validity challenge; enforcement is uncertain and jurisdiction-dependent; TERMINATION ON CHALLENGE: many licenses include a clause terminating the license automatically if the licensee challenges validity; the licensor can then sue for infringement if the challenge fails; MedImmune affects this strategy — licensees can challenge via DJ while continuing to pay, making pre-emptive termination more difficult; ROYALTY ESCALATION: if the licensee challenges validity and loses, some licenses provide for increased royalty rates; functions as a disincentive to challenge; LIMITATION ON RECOVERY: clauses limiting the licensee's ability to recover past royalties even if the patent is later invalidated; MPC ANTICOMPETITIVE CONCERNS: some challenge deterrence provisions may raise antitrust concerns (patent misuse) if they effectively prevent competition; ESTOPPEL AGREEMENTS: separate agreements where the licensee affirmatively agrees not to challenge validity in exchange for favorable license terms; validity of such standalone agreements varies by jurisdiction.